Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: TK-112690: The dose of TK-112690 is 45 mg/kg administered weekly for 4 consecutive weeks as an iv infusion one hour before methotrexate and five hours after methotrexate infusion over a
Sponsors
TOSK INC
Eligibility
Inclusion criteria
Inclusion criteria: Male and female subjects over 18 years old with a histologically or cytological confirmed diagnosis of locally residual, recurrent or metastatic SCCHN. Subject must have failed at least onecourses of non-MTX chemotherapy, orone course of non-MTX chemotherapyand chemo radiation for treating their SCCHN. No prior systemic treatments for cancer (chemotherapy and/or radiotherapy) 4 weeks prior to screening. No other concurrent, active, invasive malignancies. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Must have a life expectancy of at least 6 months. History of brain metastases allowed if disease has stabilized or improved after radiation and/or craniotomy. No active angina or uncontrolled arrhythmia. No detectable infection including hepatitis B/C and HIV. Not pregnant or nursing. Women of childbearing potential must have a negative urine pregnancy test at screening and on the day before dosing and must use medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condoms, spermicidal foam, IUD, progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or post-menopausal for >= 1 year, must be specified in the patientâ??s medical history file and CRF. Must have adequate organ and immune function as indicated by the following laboratory values: Parameter Laboratory Values Serum creatinine Est. creatinine clearance >=45 mL/min Total bilirubin AST & ALT Absolute granulocytes >=1.5 x 109 cells/L Platelets >=100,000/µL Be able to read orunderstand, and provide a signature or thumb impression on the Informed Consent Form (ICF) before entering the study.
Exclusion criteria
Exclusion criteria: Subject has not failed at least onecourses of non-MTX chemotherapyor one course of non-MTX chemotherapy and chemo radiation for treating their SCCHN. Uncontrolled active infection. Current mucositis ( >Grade 1). Pregnant or nursing mother. Prior history of a cerebrovascular accident or hemorrhage. Congestive heart failure, as defined by New York Heart Association class III or IV. Uncontrolled hypertension. Active psychiatric/mental illness making informed consent or useful clinical follow-up unlikely. Subjects who have previously been enrolled into this study and subsequently withdrew. Subject receiving other investigational agent(s). Any systemic immunosuppressive medication/therapy (eg, other chemotherapy, steroids). Any significant systemic illness, unstable or severe medical condition(s) that could put the subject at risk during the study, interfere with outcome measures, or affect compliance with the protocol procedures such as intercurrent infection and/or autoimmune disease, ie, any condition that compromises the immune system. Known or suspected intolerance or hypersensitivity to the study materials (TK-112690 and/or excipients or closely related compounds). Subjects, who have received, or plan to receive, radiation or chemotherapy within 4 weeks of screening. Subjects that have a history of poor compliance in clinical research studies. Subjects that have participated in any other investigative clinical trial in the past 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine pilot efficacy of an iv infusion of TK-112690 to placebo as a mucositis preventive in subjects with locally advanced, residual, orrecurrent or metastatic SCCHN scheduled to receive MTX as chemotherapy.Timepoint: Patients will be evaluated for extent and severity of mucositis using established mucositis rating scales, e.g., OMAS/Sonis, PROMS, WHO, and CTCAE/mucositis on the day prior to study start (Day 0), and 24 and 48 hours post each initial infusion of TK-112690/ placebo as well as on Day 1 of Week 6. | — |
Secondary
| Measure | Time frame |
|---|---|
| Confirmation of the safety/tolerability of a continuous administered weekly for 4 weeks and lowering of plasma concentrations of surrogate markers of mucositis, e.g., CD40/CD40L, post TK-112690 in patients suffering from local, advanced, residual or recurrent, metastatic SCCHN receiving sequential continuous iv infusions of TK-112690 and MTX or TK-112690 placebo and MTX.Timepoint: Predose and postdose 24 hr and 28 hr safety samples for 4 week.6 week safety sample.also surrgoate Biomarkers at every week . | — |
Countries
India
Contacts
Public ContactDr Sagar Bhosale
Crystal Life Sciences
Outcome results
None listed